Status:
COMPLETED
Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
Lead Sponsor:
Agennix
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to study the combination regimen of satraplatin and paclitaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).
Detailed Description
This trial is designed to study the efficacy and safety of a novel oral platinum analog, satraplatin, in combination with another chemotherapy drug, paclitaxel, for the first line of treatment (patien...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically confirmed advanced NSCLC
- Patients must not have received any prior antineoplastic chemotherapy or investigational product for lung cancer prior to study entry.
- Patients must have at least one unidimensionally measurable lesion definable by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
- ECOG performance status of ≤ 2.
Exclusion
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00268970
Start Date
December 1 2005
End Date
September 1 2009
Last Update
April 30 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203